Masoud Soleimani
Masoud Soleimani is an expert in Biochemistry at Tarbiat Modares University (Iran). As of August 2026, ScienceLeadR ranks Masoud Soleimani in the top 1% of experts worldwide for Tissue Engineering and Cell Engineering. Masoud Soleimani has authored 728 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 2 of them ongoing. SLR score: 1,749 (community average: 125). How the SLR is computed.
LeadR Profile
Biochemistry
Subspecialties: Immunology - Oncology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2008 - 2026
Number : 728
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Mesenchymal Stem Cell-Derived Exosomes as a Double-Edged Sword: Balancing Inflammation and Immunosuppression in Human Papillomavirus-Infected Tissues. PMID 42519494 — cells, immunomodulation, microscopy, electron, scanning transmission, neoplasms, stem cells, mesenchymal stem cells, exosomes, therapeutics, alphapapillomavirus, tissues, immunosuppression therapy, papillomavirus infections, infections, human papillomavirus viruses | Stem Cells Int | 2026 | 0 |
| COX-2- and IDO-associated immunomodulatory functions of stage II carcinoma-associated fibroblasts in breast cancer. PMID 42423754 — cytokines, cells, genes, breast neoplasms, neoplasms, breast, immunity, fibroblasts | J Mammary Gland Biol Neoplasia | 2026 | 0 |
| Human umbilical cord mesenchymal stem cells derived exosomes enhance the therapeutic efficacy of anti-miR-10b in glioblastoma. PMID 42225668 — cells, microscopy, electron, scanning transmission, neoplasms, stem cells, mesenchymal stem cells, exosomes, glioblastoma, therapeutics, umbilical cord, antagomirs | Sci Rep | 2026 | 0 |
| Cord-blood-PRP attenuates fibrogenic features of TGFβ-activated hepatic stellate cells in in vitro and animal models. PMID 41844050 — cells, genes, hepatic stellate cells, growth, vascular endothelial growth factor a, blood, tissue inhibitor of metalloproteinases, biochemistry, fibrosis, collagen, transaminases, liver, therapeutics, tissues | Bioorg Chem | 2026 | 0 |
| In vitro Safety and Immunotoxicity Assessment of a Novel mRNA-LNP Vaccine against Cytomegalovirus: Insights into Safety and Immunomodulatory Profiles. PMID 41674172 — cytokines, cells, safety, vaccines, rna, messenger, cytomegalovirus, complement system proteins, complement activation, lipid nanoparticles | Iran J Allergy Asthma Immunol | 2026 | 0 |
Clinical Studies 3
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Cell Therapy with Anti CD19 CAR NK Cells in Patients with Relapsed or Resistant B ALL NCT06631040 — cytokines, burkitt lymphoma, cells, precursor cell lymphoblastic leukemia-lymphoma, laboratories, safety, killer cells, natural, lymphoma, cyclophosphamide, neoplasms, informed consent, leukemia, leukemia, lymphoid, cytokine release syndrome, drug-related side effects and adverse reactions, therapeutics, conditioning, psychological | Phase 1/Phase 2 | Not yet recruiting | 2024 |
| Effect of Ev FV on Wound Healing in Dystrophic Epidermolysis Bullosa NCT07230223 — skin, cells, epidermolysis bullosa dystrophica, safety, blister, epidermolysis bullosa, therapeutics, men | Phase 1/Phase 2 | Recruiting | 2024 |
LeadR Networks
Main global connection map